The EPLC and Swiss HLG are delighted to invite you to the 14th International Pharmaceutical Licensing Symposium; Peak Performance. To be held in Montreux, Switzerland, 19th – 21st September 2018.
Program-
This year the EPLC have put together a program with the theme of Peak Performance designed to help you evolve your deal-making in an ever-changing Business Development environment.
To take a look at the detailed program clickXIV-IPLS-Montreux-Programme-July-Update
Why you should register
Who should attend
Business Development Executives, General Managers, Directors, Owners, Executives in Marketing, Regulatory & Finance from the Healthcare sector, from all countries
Financing and Deal-making in turbulent times, 2nd March 2021, 3.00pm – 6.00pm CET
Digital Health – Accelerated by the pandemic, 13th April 2021, 3.00pm – 6.00pm CET
Creative ways to access Innovation, 1st June 2021, 3.00pm – 6.00pm CET
Adapting ongoing clinical trials
Adapting business plans and operations
Industrial association and government resources
Health authority guidelines
Swiss task forces and initiatives
Partnering & collaboration resources
Sales & marketing resources
Scientific/academic publications
Scientific materials and tools (reference samples etc)
Diagnostic, Therapeutic & Vaccine developments
Heathcare Conferences
Hackathon
Interesting Reads / Literature
The Swiss HLG, a non-profit association of Business Development and Licensing professionals, held its 31st Conference titled “DEAL-MAKING IN THE ROUGH”, in a beautiful setting in the Swiss Alps. The topic of discussion focused on the fact we are living in provoking times: The pharmaceutical and biotech industry as a whole and the professional business developers, alliance managers and dealmakers have to cope with a disruptive and changing environment in which deal making will become more and more complex and ambitious.
Over two and a half days, more than 85 delegates from Switzerland, Europe, the US and Asia gathered in the Swiss Alps to explore and discuss new trends in partnering and deal-making in the current tumult of our industry with the overall objective to capture the maximum value with professional capabilities and high-calibre talents.
